Access the “What This Means” segment here BOSTON and LONDON, June 25, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel ...

After a thorough examination, the doctor may also order an antibody nuclear (ANA) test, which will let them know if any autoantibodies (blood proteins) are in the blood. However, because our bodies ...

We describe the preparation and characterization of synthetic antibodies based on molecularly imprinted polymer nanoparticles (MIP-NPs) for the recognition and binding of the highly conserved and ...

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across IndiaDifferentiated PH1 payload ...

News & Views Published: December 2008 Short-circuiting RNA splicing Matthew D Disney Nature Chemical Biology 4, 723–724 (2008) Cite this article ...

Akari Therapeutics is an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs). The Company has developed its first novel payload, PH1, a spliceosome inhibitor ...

Despite the different alleles, or variations in the human genome that exist in antibody genes, most humans have gene alleles that can contribute to making these antibodies. The research team then ...

When the antibody was injected into the retinas of mice afflicted with retinitis pigmentosa, the action of PROX1 was blocked, retinal regeneration was restored, and vision returned for a period of ...

The United States could soon have another tool in the fight against respiratory syncytial virus, an illness that’s the No. 1 cause of hospitalization in infants.

A third monoclonal antibody product to protect babies against respiratory syncytial virus was approved by the Food and Drug Administration on Monday, a development public health experts hope may ...